G. Steven Burrill
CEO, Burrill & Company

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He serves as Chairman of the Boards of Pharmasset, BioImagene and NewBridge, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed, Ikano Therapeutics, ProteoGenix, Proventys, Targacept and XDx. Before founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the Scientific American magazine (The Scientific American 50).

Mr. Burrill is a founder and Chairman of the Board of the Foundation for the National Medals of Science and Technology. He serves as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MayBAC). He serves on the Boards of the Bay Area Science Infrastructure Consortium, BayBio (Emeritus), California Healthcare Institute (Emeritus), The Exploratorium, The Kellogg Center for Biotechnology, the University of Maryland Biotechnology Institute, the MIT Center for Biomedical Innovation, Kramden Institute, and the National Health Museum. He also serves on the Purdue Discovery Park External Advisory Committee and on the editorial board of the Journal of Commercial Biotechnology and is on the advisory board of the Center for Policy on Emerging Technologies (C-PET). He is an advisor to the University of Illinois Institute for Genomic Biology, University of Wisconsin - College of Agriculture and Life Sciences, University of Minnesota College of Biological Sciences, Duke University, and is an adjunct professor at University of California, San Francisco.

Back to Confirmed Speakers